‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.
It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.
​
A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.
​
PRIMAVERA is part of the AMR Accelerator Programme.
At a glance
Innovations to accelerate vaccine development and manufacture
